

**Anti-Complement component C9 (human)**

**Mouse monoclonal antibody**

Subclass: IgG1/k

CAT. NO.

**ABS 004-53**

Clone: C9 53

---

SPECIFICITY	ABS 004-53 is specific for complement factor C9
IMMUNOGEN	Complement factor C9
TESTED APPLICATIONS	ELISA
SPECIES REACTIVITY (POSITIVE)	Human
SPECIES REACTIVITY (NEGATIVE)	Not determined
EPILOPE SPECIFICITY	Not determined

---

**PRESENTATION**

Content:	Available in 400 µL and 1 mL size. 1 mg/mL +/- 15%. See Certificate of Analysis for details.
Preparation:	Protein-A purified
Form:	Liquid
Solvent:	0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
Storage:	4-8°C without exposure to light. No precautions necessary during handling.

---

**APPLICATION**      **ELISA:** ABS 004-53 recognizes C9 in human serum diluted 1/50 in Tris buffer (20 mM Tris-base, 1 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub> and 140 mM NaCl) and incubated for 2 hours at 37°C using a human IgM coated (10 µg/mL overnight at 4°C, blocked with PBS 7.2 + 1% BSA for 1 hour) ELISA plate.

**TARGET**            Complement factor C9 is a 71kDa single-chain ellipsoid a-globular molecule of 558 amino acids including a leader sequence of 20 amino acids. C9 bind the C5b8 complex on membranes and has a unique property in forming tubular structures containing between 12 and 18 monomers, closely resembling the membrane attack complex (MAC). The primary site of synthesis is hepatocytes, secondary sites are monocytes, fibroblasts and glial cells. The normal level of C9 in plasma is 60 µg/mL, and the level is up regulated from hepatocytes by IFN-γ.

**REFERENCES**

**CONDITIONS**

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.